New hope for tough leukemias: experimental drug combo enters human testing
NCT ID NCT04874480
First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 18 times
Summary
This early-phase trial tests a new drug called tegavivint, combined with decitabine, in 9 adults with leukemia that has come back or not responded to standard treatments. The goal is to find the safest dose and see if the combination can control the disease. Participants must have no other standard options and cannot have had leukemia therapy for 14 days before starting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.